[Ip-health] USA - Australia FTA; Impact on pharmaceuticals
Ken Harvey
k.harvey@latrobe.edu.au
Thu Mar 4 18:54:07 2004
USA - Australia Free Trade Agreement: Impact on pharmaceuticals
This agreement [1] contains major concessions to the US pharmaceutical
industry that are likely to undermine the Australian Pharmaceutical Benefits
Scheme (PBS) and ultimately increase the costs of medicinal drugs to
Australian consumers.
The agreement is unbalanced in that it focuses entirely on the rights of
pharmaceutical manufacturers and totally neglects the rights of consumers to
equitable access to affordable drugs. In particular the agreed principles on
pharmaceuticals (FTA Annex 2C) leave out the key principle of the Doha
Declaration [2] on the TRIPS Agreement and Public Health, adopted by the WTO
Ministerial Conference in November 2001, namely that trade agreements should
be interpreted and implemented so as to protect public health and promote
access to medicines for all.
The FTA allows pharmaceutical manufactures to ask for an independent review
of a decision by the Australian Pharmaceutical Benefits Advisory Committee
(PBAC) not to list a drug because the evidence showed it not to be
cost-effective. This is despite the fact that such appeals were previously
rejected by a review of PBS processes held in 2000. Appeals against PBAC
decision-making are likely to favour multi-national pharmaceutical companies
who have large budgets and numerous lawyers; inevitably they will lead to
drugs being listed at higher prices; why else would companies want such
provision?
The exchange of letters between Trade Minister Vaile and US Ambassador
Zoellick also shows that Australia shall provide opportunities for
pharmaceutical manufacturers to apply for an adjustment to PBS prices over
time. There appears no corresponding provision for price adjustment
downwards when pharmaceutical manufacturers cause PBS blow-outs by excessive
advertising encouraging inappropriate use, a well documented tactic in
recent years. [3]
The agreement sets up a medicines working group with the USA, a country
which many people argue has the worst (most inequitable, highest priced)
pharmaceutical system in the world. Yet the public health goal of equitable
(affordable) access is not a consideration of this FTA or the working group.
If it was, then the USA and its citizens who now go to Canada and Mexico to
buy affordable drugs could learn much from the Australian PBS.
The provision about dissemination of pharmaceutical information via the
Internet raises concern that this will allow Direct to Consumer Advertising
(DTCA) in Australia by default. DTCA is legal in the USA but not in
Australia. It has been associated with a substantial increase in usage of
the products targeted (and thus health care costs) which are often not in
accord with best-practice. [4]
Finally, although not part of Annex 2-C on Pharmaceuticals, there appears to
be extensive changes to Australian patent laws which are likely to delay the
introduction of cost-effective generic drugs. These changes are likely to
lead to increased PBS costs and increased costs of over-the-counter (OTC)
medicines. [5]
In conclusion, it is very sad that at the same time that the Australian
Health Insurance Commission is successfully exporting Australian medicinal
drug policy to many countries who are struggling to balance health policy
with industry policy, the current Australian government has totally ignored
public health considerations in a one-sided trade agreement with the USA.
Beware of Free Trade Agreements with the USA!
References
1. http://www.dfat.gov.au/trade/negotiations/us.html
2. http://www.who.int/medicines/organization/ood/trips_med.shtml
3. http://www.mja.com.au/public/issues/179_08_201003/dow10457_fm-2.html
4. http://www.chspr.ubc.ca/hpru/pdf/dtca-v1-execsum.pdf
5. http://www.tai.org.au/WhatsNew_Files/WhatsNew/Patents.pdf
-----------------------------------
Dr. Ken Harvey, Council Member, Australian Consumers Association; Board
Member Therapeutic Guidelines Ltd.; Senior Lecturer, School of Public
Health, La Trobe University; http://users.bigpond.net.au/medreach/
________________________________
From: Rebecca.de.Boer@health.gov.au
[mailto:Rebecca.de.Boer@health.gov.au]
Sent: Friday, 5 March 2004 9:49 AM
To: s.Barraclough@latrobe.edu.au; K.Harvey@latrobe.edu.au
Subject: Re: Information session - pharmaceutical issues and the
AUSFTA, conducted by the Dept of Health and Ageing
Simon/Ken,
You are both welcome to come to these sessions if you are in CBR.
Could you let me know?
Thanks,
Rebecca
You are invited to attend an information session on pharmaceutical
issues
and the AUSFTA (Australia-United States Free Trade Agreement) and,
in
particular, the implications for the Pharmaceutical Benefits Scheme.
Chair: Ms Joan Corbett
Assistant Secretary, Pharmaceutical Benefits Branch
Presenters: Dr Ruth Lopert
Medical Adviser, Pharmaceutical Benefits Branch
Ms Carolyn Smith
Health Liaison
Australia-United States Free Trade Agreement
Dates: Monday 8th of March 2004
10AM - 11.30AM
Conference Room 3
Ground Floor
Alexander Building, Woden
Tuesday 16th of March 2004
2PM - 3.30PM
Executive Conference Room
7th Floor
Alexander Building, Woden
Please nominate which session you would like to attend when you
RSVP.
RSVP: 5th of March
Chris Kilpatrick
Pharmaceutical Benefits Branch
6289 7084
****************************************************************************
****
"Important: This transmission is intended only for the use of the
addressee and
may contain confidential or legally privileged information.
If you are not the intended recipient, you are notified that any use
or
dissemination of this communication is strictly prohibited. If you
receive this
transmission in error please notify the author immediately and
delete all copies
of this transmission."
****************************************************************************
****